Toronto Raptors guards Kyle Lowry and Fred VanVleet were saddened by Norman Powell getting traded but are proud of what he's done in his NBA career.
Toronto Raptors guards Kyle Lowry and Fred VanVleet were saddened by Norman Powell getting traded but are proud of what he's done in his NBA career.
BOISE, Idaho — The Idaho Senate on Wednesday approved legislation allowing the state to hire private contractors to kill up to 90% of the wolves roaming Idaho. The agriculture industry-backed bill approved Wednesday on 26-7 vote includes additional changes intended to cut the wolf population from about 1,500 to 150. “These wolves, there’s too many in the state of Idaho now,” said Republican Sen. Mark Harris, one of the bill's sponsors, during debate on the Senate floor. “We’re supposed to have 15 packs, 150 wolves. We’re up to 1,553, was the last count, 1,556, something like that. They’re destroying ranchers. They’re destroying wildlife. This is a needed bill.” The Idaho Department of Fish and Game reported in February that the wolf population has been holding at about 1,500 the past two years. The numbers were derived by using remote cameras and other methods. About 500 wolves have been killed in the state in each of the last two years by hunters, trappers and wolf-control measures carried out by state and federal authorities. Republican Sen. Van Burtenshaw, another of the bill's sponsors, downplayed the number of wolves to be killed while debating the bill. “The purpose of this legislation is to control the population, not to wipe them out,” he said. “There’s never been any discussion in the working group of complete annihilation of the wolf population, or killing 90% of the wolves.” However, Burtenshaw the previous day at a committee hearing for the bill cited numbers contained in Idaho’s 2002 wolf conservation and management plan. The plan calls for at least 150 wolves and 15 packs in Idaho. He said the state is allowed to increase the killing of wolves to reach that level. If the wolf population falls below 150, the killing of wolves would have to be reduced. Also according to the plan, if Idaho’s wolf population fell to 100, there’s a possibility the U.S. Fish and Wildlife Service could resume management of its wolf population. The 2002 document says wolf management could revert to what was in place when wolves were listed under the federal Endangered Species Act. Democratic Sen. Grant Burgoyne noted nothing in the proposed law prevented the killing of wolves down to 150. “We do know that if we want to maintain our agreement with the federal government, we need to stop at 90%,” he said. “That's what we know.” A primary change in the new law is the hiring of private contractors to kill wolves. The legislation includes increasing the amount of money the Idaho Department of Fish and Game sends to the Idaho Wolf Depredation Control board from $110,000 to $300,000. The board, created in 2014, is an agency within the governor’s office that manages state money it receives to kill wolves. Other changes in the legislation include removing any limit on the number of wolf tags issued to a hunter, meaning there would be no restriction on how many wolves one person is allowed to kill. Wolves, though, have proved difficult to find and kill for the vast majority of hunters and trappers. The legislation also combines a hunting tag with a trapping and snaring tag, meaning only one tag is needed for those combined methods. Wolf trapping would be allowed year-round on private land. In addition, the legislation makes changes to allow hunting wolves with ATVs and snowmobiles and other methods allowed for animals classified as predators, such as coyotes. Also, state agencies outside of Idaho would be allowed to kill wolves in Idaho. The measure now goes to the House. “The Idaho Senate’s sudden move to pass this bill in the eleventh hour incentivizes the cruel deaths of more than 1,000 wolves across the state,” said Andrea Zaccardi, a senior attorney at the Center for Biological Diversity. “The consequences of this bill will be horrendous. This brutal war on wolves must be stopped, and we urge the House to deny this bill.” Keith Ridler, The Associated Press
A Texas school district created a new dress code after a student says he was suspended for wearing nail polish.
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ubiquiti Inc. ("Ubiquiti" or the "Company") (NYSE: UI). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.The investigation concerns whether Ubiquiti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the ...
Jeffrey Kightlinger, general manager of the Metropolitan Water District of Southern California, issues the following statement on today’s emergency drought proclamation by Gov. Gavin Newsom for two counties while ordering a prioritization of available state resources:
SALT LAKE CITY — Pain left from oil-field work defeated traditional pain pills and dominated William Adams’ life — until he tried medical marijuana. But even as he began venturing outside his home for the first time in years, Adams discovered he couldn't afford the cost. Medical cannabis typically isn't covered by insurance or Medicaid because it remains federally illegal. The group that led the push to legalize it in conservative Utah says that has kept it unreachable for many patients who need it. The Utah Patients Coalition on Tuesday joined a small but growing list of programs around the U.S. aimed at helping low-income patients access the drug. The project is among the first to offer ongoing subsidies statewide. “I thought that we had relieved a lot of suffering, and I can’t deny that we have,” said Desiree Hennessy, executive director of Utah Patients Coalition. “But then the phone calls have changed from ‘Hey I need help, I need cannabis’… to ‘I can’t afford to go to the doctor.’ ” The coalition has partnered with cannabis pharmacies across the state that will offer discounted medications to patients approved for the subsidy. Similar programs include one in Berkeley, California, for patients making less than $32,000 a year. They can access medical cannabis for free at local medical dispensaries through a city ordinance. States like Florida and Oregon offer reduced prices for state medical cannabis cards. In New Mexico, a longstanding proposal to create a “low-income medical patient subsidy fund” to underwrite medical marijuana purchases failed this year as the state legalized recreational pot during a special session. New Mexico soon will waive taxes that currently apply to medical marijuana sales and the new cannabis excise tax for medical patients — a discount of nearly 20% in most cases. The lead House sponsor of the successful legalization bill there has vowed to reboot social and economic justice provisions that were stripped from the legislation. Emily Kaltenbach, a senior director at the Drug Policy Alliance, said subsidy programs like the one in Utah are critical for low-income patients who have limited options to be able to afford their medicine. One challenge the Utah program may face is raising enough money to keep it going long term, she said. “We see patients who not only can’t afford their medicine but they also can’t afford doctor’s visits,” said Kaltenbach, who is based in New Mexico. “Many of them are uninsured and so the cost of the visit to get certified to be a patient and then the cost of medicine can have a huge impact.” Dragonfly Wellness, Utah’s first marijuana pharmacy, announced Tuesday that it would be donating $130,000 to the subsidy program, which will be entirely funded by donations. Hennessey had tears in her eyes as she described the impact that money will have on patients’ lives. She said it will likely cover the cost of subsidizing medication for the more than 400 terminal patients who have applied for the program. “I have hope that we are actually going to fill the need,” she said. Utah became the 33rd state to legalize medical marijuana after voters passed a ballot initiative in November 2018, though the program has especially tight controls under a compromise involving The Church of Jesus Christ of Latter-day Saints, whose positions carry outsized sway in its home state. After contacting his cannabis pharmacy about his financial concerns, Adams, 38, became the first person to pilot the coalition’s subsidy program in January. Now his pain has subsided enough that he can go out and enjoy the parts of life he had been missing out on — spending time with his family, fishing and even riding his motorcycle. “I’m a whole different person with a whole better life than I was six months ago,” Adams said. “Being able to manage pain correctly, it just changes everything in every way.” ___ Associated Press writer Morgan Lee in Santa Fe, New Mexico, contributed to this story. ___ Eppolito is a corps member for the Associated Press/Report for America Statehouse News Initiative. Report for America is a non-profit national service program that places journalists in local newsrooms to report on undercovered issues. Sophia Eppolito, The Associated Press
The most memorable moment of “Rutherford Falls” — featuring two characters sitting opposite each other and just talking with startling honesty — deviates sharply from the show’s established norm. Otherwise, the new comedy from Ed Helms, Sierra Teller Ornelas and uber-producer Michael Schur focuses on hapless heir Nathan Rutherford (Helms) trying to preserve his family […]
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of MultiPlan Corporation (NYSE: MPLN), Ebang International Holdings, Inc. (NASDAQ: EBON), 3D Systems Corporation (NYSE: DDD), and Amdocs Limited (NASDAQ: DOX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Multiplan Corporation (NYSE: MPLN) Class Period: Securities purchased between July 12, 2020 and November 10, 2020, inclusive (the “Class Period”) and all holders of Churchill III Class A common stock entitled to vote on Churchill III’s merger with and acquisition of Polaris Parent Corp. and its consolidated subsidiaries (collectively, “MultiPlan”), which was consummated in October 2020 (the “Merger”). Lead Plaintiff Deadline: June 7, 2021 Churchill III is a blank check company that merged with MultiPlan, a healthcare cost specialist. In July 2020, Churchill III announced that it had entered into a preliminary agreement, subject to shareholder approval, to merge with MultiPlan. MultiPlan is a New York-based data analytics end-to-end cost management solutions provider to the U.S. healthcare industry. The Multiplan class action lawsuit alleges that defendants made materially false and misleading statements in connection with the Merger and during the Class Period regarding the business, operation, and prospects of MultiPlan. On November 11, 2020 – only one month after the close of the Merger – Muddy Waters published a report on Churchill III titled “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab” (the “Muddy Waters Report”). Among other revelations, the Muddy Waters Report revealed that MultiPlan was in the process of losing its largest client, UnitedHealthcare, which was estimated to cost the Company up to 35% of its revenues and 80% of its levered free cash flow within two years. As a result of this news, the price of Churchill III securities plummeted. By November 12, 2020, the price of Churchill III Class A common stock fell to a low of just $6.12 per share, nearly 40% below the price at which shareholders could have redeemed their shares at the time of the shareholder vote on the Merger. For more information on the Multiplan class action go to: https://bespc.com/cases/MPLN Ebang International Holdings, Inc. (NASDAQ: EBON) Class Period: June 26, 2020 and April 5, 2021 Lead Plaintiff Deadline: June 7, 2021 On April 6, 2021, Hindenburg Research published a report alleging, among other things, that Ebang is directing proceeds from its IPO last year into a “series of opaque deals with insiders and questionable counterparties.” According to the report, Ebang raised $21 million in November 2020, claiming the proceeds would go “primarily for development,” and that instead the funds were directed to repay related-party loans to a relative of the Ebang’s Chief Executive Officer, Dong Hu. The report also noted that Ebang’s earlier efforts to go public on the Hong Kong Stock Exchange had failed due to widespread media coverage of a sales inflation scheme with Yindou, a Chinese peer-to-peer online lending platform that defrauded 20,000 retail investors in 2018, with $655 million “vanish[ing] into thin air.” On this news, the Company’s share price fell $0.82, or approximately 13%, to close at $5.53 per share on April 6, 2021. On April 6, 2021, after the market closed, Ebang issued a statement stating that, though it believed the report “contain[ed] many errors, unsupported speculations and inaccurate interpretations of events,” the “Board, together with its Audit Committee, intends to further review and examine the allegations and misinformation therein and will take whatever necessary and appropriate actions may be required to protect the interest of its shareholders.” On this news, the Company’s share price fell $0.12, or 2.17%, to close at $5.41 per share on April 7, 2021. The stock price continued to decline over the next trading session by $0.38, or 7%, to close at $5.03 per share on April 8, 2021. The complaint, filed on April 8, 2021, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the proceeds from Ebang’s public offerings had been directed to an low yield, long term bonds to an underwriter and to related parties rather than used to develop the Company’s operations; (2) that Ebang’s sales were declining and the Company had inflated reported sales, including through the sale of defective units; (3) that Ebang’s attempts to go public in Hong Kong had failed due to allegations of embezzling investor funds and inflated sales figures; (4) that Ebang’s purported cryptocurrency exchange was merely the purchase of an out-of-the-box crypto exchange; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. For more information on the Ebang class action go to: https://bespc.com/cases/EBON 3D Systems Corporation (NYSE: DDD) Class Period: May 6, 2020 to March 1, 2021 Lead Plaintiff Deadline: June 8, 2021 On March 2, 2021, 3D Systems filed a NT-10-K with the SEC, stating that their 10- K filing would be delayed. On this news, 3D Systems’s stock price fell $7.62 per share, or more than 19.6%, from closing at $38.79 per share on March 1, 2021 to close at $31.17 per share on March 2, 2021, damaging investors. The complaint, filed on May 9, 2021, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) 3D Systems lacked proper internal controls over financial reporting; and (2) as a result, 3D Systems’ public statements were materially false and/or misleading at all relevant times. For more information on the 3D Systems class action go to: https://bespc.com/cases/DDD Amdocs Limited (NASDAQ: DOX) Class Period: December 13, 2016 to March 30, 2021 Lead Plaintiff Deadline: June 8, 2021 Amdocs, through its global subsidiaries, provides software and services to communications, cable and satellite, entertainment, and media industry service providers worldwide. Historically, the Company’s largest percentage of revenues come from its North American business, mostly the U.S., particularly from large customers including, among others, AT&T Inc. (“AT&T”). On March 31, 2021, Jehoshaphat Research (“Jehoshaphat”) published a short-seller report addressing Amdocs, which alleged that Amdocs overstated its profits, evidenced by steady parent profits despite declining subsidiary profits; that there was a concerning pattern of reputable auditors resigning, only to be replaced by “scandal-plagued or tiny shops”; that Amdocs “window-dressed” its balance sheets to keep its large borrowing a secret, namely by paying down its debt just prior to the end of each quarter, therefore showing a debt-free balance sheet on that day, before reborrowing the money shortly thereafter; and that all of the foregoing was corroborated by former employees and direct competitors of the Company, who noted that Amdocs was losing AT&T as a customer, as well as a former American Amdocs executive, who stated that the Company’s “US business was declining at a rate of [around] 7% annually . . . but then we would see the company [publish results that] say North America is stable.” On this news, Amdocs’ ordinary share price fell $9.19 per share, or 11.58%, to close at $70.15 per share on March 31, 2021. The complaint, filed on April 9, 2021, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs’ reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. For more information on the Amdocs class action go to: https://bespc.com/cases/DOX About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Melissa Fortunato, Esq.Marion Passmore, Esq.(212) firstname.lastname@example.org
Boston, Massachusetts--(Newsfile Corp. - April 21, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that a lawsuit for violations of the federal securities laws has been filed against Leidos Holdings, Inc. (NYSE: LDOS) and certain of its executives. If you purchased or acquired shares of Leidos between May 4, 2020 and February 23, 2021, you are strongly encouraged to contact Block & Leviton attorneys at (617) 398-5600, ...
Cutera, Inc. to Announce First Quarter Results on May 5, 2021
The Roundtable on Sustainable Palm Oil (RSPO) has released its Practical Guidance on Gender Inclusion and Compliance to the 2018 RSPO Principles and Criteria (P&C) and the 2019 Independent Smallholder (ISH) Standard. Developed by the RSPO Human Rights Working Group (HRWG), in consultation with Fair & Sustainable Consulting, this Gender Guidance underscores the vital role that women play in the palm oil industry and the need to strengthen our commitment to women's rights.
New learning programme aims to mainstream science-based targets so more companies can deliver ambitious climate action for a net-zero futureNew York, NY, April 21, 2021 (GLOBE NEWSWIRE) -- UNITED NATIONS, New York, April 22 2021 — With 500 companies already committed to the Business Ambition for 1.5°C campaign, the United Nations Global Compact has today launched the Climate Ambition Accelerator, a six-month learning programme to equip more companies with the knowledge and skills they need to help halve global emissions by 2030 and to reach net-zero by 2050. “This is a make or break year to confront the climate emergency. Meaningful actions taken by businesses collectively now have the power to limit global warming to 1.5 degrees C. Our new Climate Ambition Accelerator enables more companies in our Local Networks to join the transition to a net-zero future and get started in setting ambitious, credible science-based targets,” said Sanda Ojiambo, CEO & Executive Director of the UN Global Compact. Led by the UN Global Compact with support from patrons Ørsted and Natura &Co, and sponsored by En+ Group, the Climate Ambition Accelerator aims to scale-up credible climate action across companies of all sizes, sectors and regions, to enable them to set and deliver on meaningful commitments to reduce emissions and deliver on the Paris Climate Agreement. The new programme builds on the UN Global Compact’s work to develop and promote the Science Based Targets initiative and the Business Ambition for 1.5°C campaign. It also complements the Global Compact’s existing environmental sustainability efforts such as the Action Platform on Climate Ambition, the Sustainable Ocean Business Action Platform and the Water Resilience Coalition, which in turn contribute to the Race to Zero and Race to Resilience campaigns in the lead up to COP26. Through the Global Compact Local Networks around the world, companies participating in the Climate Ambition Accelerator will gain access to best practices, peer-to-peer learning opportunities, capacity building sessions and on-demand training. The Climate Ambition Accelerator aims to engage 750 companies, including SMEs, across industries in more than 25 countries to focus on setting science-based targets. Companies of all sizes are encouraged to apply for the accelerator programme at unglobalcompact.org/climate-ambition-accelerator. Mads Nipper, CEO of Ørsted said: “Companies can and must be catalysts for green action. We believe that the companies that will thrive in 10 or 20 years from now, are those that take a fundamentally sustainable approach. That’s why Ørsted is honoured to be a patron of the UN Global Compact’s Climate Ambition Accelerator, which aims to help companies put carbon reduction at the heart of their business. By sharing insights on how Ørsted has transformed sustainably and performed well at the same time, we hope to inspire companies globally to engage in a faster green transformation." Roberto Marques, Executive Chairman and Group CEO for Natura &Co said: “This is the decade for action to address the climate crisis and we have no time to lose. Every business needs to commit to a better, more sustainable future. It may be challenging to understand where to begin or how to get there. That's why the launch of the Climate Ambition Accelerator is so important. It will help companies to act, move faster, be more accountable, and to ultimately reach their net zero goals.” Notes to Editors: About the United Nations Global Compact As a special initiative of the UN Secretary-General, the United Nations Global Compact is a call to companies everywhere to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti-corruption. Our ambition is to accelerate and scale the global collective impact of business by upholding the Ten Principles and delivering the Sustainable Development Goals through accountable companies and ecosystems that enable change. With more than 12,000 companies and 3,000 non-business signatories based in over 160 countries, and 69 Local Networks, the UN Global Compact is the world’s largest corporate sustainability initiative — one Global Compact uniting business for a better world. For more information, please follow @globalcompact on social media and visit our website at unglobalcompact.org. Media contacts: email@example.com Alex Gee +44 7887 804594 firstname.lastname@example.org CONTACT: Media Team United Nations Global Compact (212) 907-1301 email@example.com
Around 40+ notable companies such as Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Athersys, AmKor Pharma, Histocell, Lineage Cell Therapeutics, and others have their Spinal Cord Injury drug candidates in the pipeline to influence treatment scenario.Los Angeles, USA , April 21, 2021 (GLOBE NEWSWIRE) -- Spinal Cord Injury Clinical Trials Review: A Multitude of Emerging Drugs for Better Treatment Around 40+ notable companies such as Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Athersys, AmKor Pharma, Histocell, Lineage Cell Therapeutics, and others have their Spinal Cord Injury drug candidates in the pipeline to influence treatment scenario. DelveInsight’s “Spinal Cord Injury Pipeline Insight” report provides comprehensive insights about 40+companies and 40+ pipeline drugs in the Spinal Cord Injury pipeline landscapes. It comprises Spinal Cord Injury pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Spinal Cord Injury therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Spinal Cord Injury pipeline products. Some of the key takeaways of the Spinal Cord Injury Pipeline Report HGF (KP-100IT) can be developed as a potential Spinal Cord Injury treatment. It is currently in Phase III and is being developed by Kringle Pharma. HGF was given an orphan drug designation for Acute Spinal Cord Injury by the Japanese Ministry of Health, Labour and Welfare in September 2019.In October 2019, GTX Medical and NeuroRecovery Technologies announced their merger to create a leading global company committed to developing novel neuromodulation therapies to improve people’s functional recovery with Spinal Cord Injuries. The merged entity will be known as GTX Medical BV. The merged company is developing Targeted Epidural Spine Stimulation (TESS), an implantable spinal cord stimulation system with real-time motion feedback.MT-3921, a humanized Anti-RGMa monoclonal antibody is being developed by Mitsubishi Tanable Pharma for spinal cord injury. MT-3921 is a novel investigational drug developed jointly with Osaka University (Japan). Mitsubishi Tanabe Pharma has planned to initiate a Phase II clinical trial for Spinal cord injuries (In adults, in the elderly) in June 2021. Get an overview of pipeline landscape @ Spinal Cord Injury Clinical Trials Analysis Spinal Cord Injury is traumatic damage or nerves at the end of the spinal canal. This affects the conduction of sensory and motor signals across the site of the lesion. This disease is a debilitating neurological condition with a tremendous socio-economic impact on affected individuals and the health care system. Spinal Cord Injuries patients require multidisciplinary care management to achieve optimal health outcomes. Treatments for chronic Spinal Cord Injury focus on avoiding or improving distinct pathophysiological mechanisms, such as glial scar formation, demyelination, and astrogliosis. Treatment strategies for acute Spinal Cord Injury are limited to preventing further damage; the therapeutic approach for chronic Spinal Cord Injury focuses on promoting neuronal regeneration and treating accompanying symptoms of chronic complications. Spinal Cord Injury Emerging Drugs KP-100IT: Kringle Pharma HGF (KP-100IT) protects neurons, promotes axons’ extension, and can be developed as a potential treatment for Spinal Cord Injury. It is currently in Phase III and is produced by Kringle Pharma. Research and Development Phase III NCT04475224: In July 2020, Kringle Pharma initiated A Non-randomized, Multicenter, and Confirmatory Study by Intrathecal Administration of KP-100IT in Subjects with Acute Spinal Cord Injury. This study is a non-randomized, multicenter, confirmatory study by intrathecal administration of KP-100IT, code of HGF (Hepatocyte Growth Factor) formulation for intrathecal injection, in subjects with acute spinal cord injury. The trial is expected to get completed by September 2022 with expected 25 enrolled participants. Results: Primary endpoints in Phase I/II, the safety and tolerability of HGF administration to acute Spinal Cord Injury patients, were confirmed. Although there was no significant difference in the change in ASIA motor score from baseline at week 24, which was used as the primary endpoint of efficacy, the HGF-treated group showed a consistent functional recovery trend throughout the 6-month observation period compared with the placebo group. Moreover, the two groups significantly differed about the change in the ASIA motor score from baseline at week 20, which was the secondary endpoint of efficacy. Thus, the proof of concept (POC) for HGF treatment in Acute Spinal Cord Injury was established. ES 135: Eusol Biotech ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. ES135 promote neurite outgrowth. The sequence of ES135 has been patented in Taiwan, the EU, China and the United States. ES135 is undergoing a multi-centre, double-blind, randomised, placebo-control study as the pivotal Phase 3 clinical trial for Spinal Cord Injury. For further information, refer to the detailed report @ Spinal Cord Injury Pipeline Therapeutics Scope of Spinal Cord Injury Pipeline Drug Insight Coverage: Global Major Players: 40+ Key PlayersProminent Players: Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Athersys, AmKor Pharma, Histocell, Lineage Cell Therapeutics, and many others. Key Drugs Profiles:40+ProductsPhases: Spinal Cord Injury Therapies Late-stage (Phase III) Spinal Cord Injury Therapies Mid-stage (Phase II)Spinal Cord Injury Therapies Early-stage (Phase I) Spinal Cord Injury Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Mechanism of Action: Angiogenesis inducing agents; Proto-oncogene protein c met modulatorsNeurogenesis stimulantsRGMA protein inhibitorsCell replacementsMyelin-associated glycoprotein inhibitors; Nogo protein inhibitorsAntioxidants; NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonistsConnexin 43 inhibitorsChemokine CXCL13 inhibitorsDecarboxylase inhibitors, Dopamine receptor agonists, Serotonin 1A receptor agonists Cartilage replacements; Cell replacements; Osteogenesis stimulants; Tissue replacementsMicrotubule-associated protein stimulants Molecule Types: Stem cell therapy Small molecule Gene therapyHuman fusion proteinMonoclonal antibodies Route of Administration: OralParenteralIntravenousSubcutaneousIntrathecalIntracerebral Product Types: MonotherapyCombinationMono/Combination Key Questions regarding Current Spinal Cord Injury Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for Spinal Cord Injury treatment?How many companies are developing therapies for the treatment of Spinal Cord Injury? How many are Spinal Cord Injury emerging therapies in the early-stage, mid-stage, and late development stages to treat Spinal Cord Injury?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Spinal Cord Injury market? Which are the dormant and discontinued products and the reasons for the same?What is the unmet need for current therapies for the treatment of Spinal Cord Injury? What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Spinal Cord Injury therapies? What are the critical designations that have been granted for the emerging therapies for Spinal Cord Injury? How many patents are granted and pending for the emerging therapies to treat Spinal Cord Injury? Table of Contents 1Spinal Cord Injury Introduction2Spinal Cord Injury Executive Summary3Spinal Cord Injury Overview4Spinal Cord Injury - Analytical Perspective In-depth Commercial Assessment5Spinal Cord Injury Pipeline Therapeutics6Spinal Cord Injury Late Stage Products (Phase III)6.1KP-100IT: Kringle Pharma6.2ES 135: Eusol Biotech7Spinal Cord Injury Mid Stage Products (Phase II)7.1PMZ-1620: Pharmazz7.2MT 3921: Mitsubishi Tanabe Pharma 8Spinal Cord Injury Early Stage Products (Phase I/II)8.1AST-OPC1: Lineage Cell Therapeutics9Spinal Cord Injury Early Stage Products (Phase I)9.1NEU-2000: AmKor Pharma10Spinal Cord Injury Pre-clinical and Discovery Stage Products10.1KAND 567: Kancera11Spinal Cord Injury Therapeutic Assessment12Spinal Cord Injury Inactive Products13Company-University Collaborations (Licensing/Partnering) Analysis14Spinal Cord Injury Key Companies15Spinal Cord Injury Key Products16Spinal Cord Injury Unmet Needs17 Spinal Cord Injury Market Drivers and Barriers18Spinal Cord Injury Future Perspectives and Conclusion19Spinal Cord Injury Analyst Views20Appendix21About DelveInsight Get a customised pipeline report @ Spinal Cord Injury Drugs Pipeline Report Related Reports Spinal Cord Injury Market DelveInsight's Spinal Cord Injury (SCI)- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Spinal Cord Injury Epidemiology forecast DelveInsight's Spinal Cord Injury (SCI) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of the disease. Chronic Spinal Cord Injury Epidemiology Forecast DelveInsight's Chronic Spinal Cord Injury - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Chronic Spinal Cord Injury in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Spinal Fusion Market DelveInsight' s Spinal Fusion - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Spinal Muscular Atrophy Market DelveInsight' s Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur firstname.lastname@example.org +1(919)321-6187 www.delveinsight.com
Max Scherzer dominates Cardinals in 1-0 win
Conservatives nationwide have introduced measures that they say will protect women’s sports.
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Porch Group Inc. ("Porch" or the "Company") (NASDAQ: PRCH). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.The investigation concerns whether Porch and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about ...
Should you call out a liar or let it slide? Here's how to figure out the right approach.
The federal mask mandate on planes is due to expire May 11. Airlines have required masks for nearly a year but the order has helped them enforce it.
Canada Economic Development for Quebec Regions
Pelosi initially thanked George Floyd for "sacrificing [his] life for justice"
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.The investigation concerns whether Provention and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining ...